Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q4 FY202020-12-31 | Q3 FY202020-09-30 | Q1 FY202020-03-31 | Q4 FY192019-12-31 | Q3 FY192019-09-30 | Q1 FY192019-03-31 |
|---|---|---|---|---|---|---|
| Research and development | $2.15M | $1.20M | $1.37M | $1.75M | $1.58M | $1.58M |
| Selling, general and administrative | $1.55M | $757.00K | $524.00K | $1.09M | $545.00K | $784.00K |
| Operating expenses | $3.70M | $1.96M | $1.90M | $2.84M | $2.12M | $2.36M |
| Operating income | −$3.70M | −$1.96M | −$1.90M | −$2.84M | −$2.12M | −$2.36M |
| EBITDA | −$3.70M | −$1.96M | −$1.84M | −$2.84M | −$2.12M | −$2.32M |
| Interest income | — | $57.00K | $1.10M | — | $72.00K | $55.00K |
| Interest expense | — | −$223.00K | −$2.00K | — | −$342.00K | −$358.00K |
| Income before taxes | −$5.86M | −$2.13M | −$794.00K | −$2.87M | −$2.39M | −$2.67M |
| Net income | −$5.86M | −$2.13M | −$794.00K | −$2.87M | −$2.39M | −$2.67M |
| EPS, basic | −$6.45 | −$2.40 | −$1.05 | −$4.65 | −$3.45 | −$10.35 |
| EPS, diluted | −$6.45 | −$2.40 | −$1.05 | −$4.65 | −$3.45 | −$10.35 |
| Diluted shares | 877.95K | 897.58K | 759.87K | 576.63K | 680.46K | 257.81K |
Figures describe Enlivex Therapeutics shares, not any token. As of Mar 25, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.